Literature DB >> 17459272

The basic biochemistry and molecular events of hormone therapy.

Elahe A Mostaghel1, Robert B Montgomery, Daniel W Lin.   

Abstract

Data regarding the molecular response of prostate cancer to hormone therapy continue to emerge, identifying a complex network of autocrine and paracrine signaling events mediating the tumor response to androgen suppression. Emerging data provide insight into cellular pathways important in the apoptotic response to therapy, including the transforming growth factor-beta, insulin-like growth factor-1, and vascular endothelial growth factor signaling axes. They also reveal mechanisms of direct antitumor cytotoxicity mediated by various hormonal agents and highlight the importance of developing antiandrogens capable of irreversibly inhibiting the androgen receptor. Accumulated data emphasize the presence of residual androgens and persistent activation of androgen receptor signaling in advanced prostate tumors despite castration. These factors suggest that a multitargeted treatment approach designed to ablate all contributions to the androgen receptor signaling axis within the prostate tumor microenvironment will be required in order for hormonal therapy to achieve optimal antitumor efficacy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17459272     DOI: 10.1007/s11934-007-0010-z

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  49 in total

1.  The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues.

Authors:  Alexandre Havt; Andrew V Schally; Gabor Halmos; Jozsef L Varga; Gabor L Toller; Judit E Horvath; Karoly Szepeshazi; Frank Köster; Kevin Kovitz; Kate Groot; Marta Zarandi; Celia A Kanashiro
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-18       Impact factor: 11.205

2.  Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells.

Authors:  J Gao; J T Arnold; J T Isaacs
Journal:  Cancer Res       Date:  2001-07-01       Impact factor: 12.701

3.  Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma.

Authors:  Enrique Castellón; Marisa Clementi; Catalina Hitschfeld; Catherine Sánchez; Dixan Benítez; Leonardo Sáenz; Héctor Contreras; Christian Huidobro
Journal:  Cancer Invest       Date:  2006 Apr-May       Impact factor: 2.176

4.  Pharmacogenetic analysis of human steroid 5 alpha reductase type II: comparison of finasteride and dutasteride.

Authors:  Nick Makridakis; Juergen K V Reichardt
Journal:  J Mol Endocrinol       Date:  2005-06       Impact factor: 5.098

5.  Prohibitin and cofilin are intracellular effectors of transforming growth factor beta signaling in human prostate cancer cells.

Authors:  Beibei Zhu; Kei Fukada; Haining Zhu; Natasha Kyprianou
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

6.  Phosphatidylinositol 3-kinase and mek1/2 are necessary for insulin-like growth factor-I-induced vascular endothelial growth factor synthesis in prostate epithelial cells: a role for hypoxia-inducible factor-1?

Authors:  Kevin D Burroughs; Jennifer Oh; J Carl Barrett; Richard P DiAugustine
Journal:  Mol Cancer Res       Date:  2003-02       Impact factor: 5.852

7.  Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression.

Authors:  Charles J Ryan; Alex Smith; Priti Lal; Jaya Satagopan; Victor Reuter; Peter Scardino; William Gerald; Howard I Scher
Journal:  Urology       Date:  2006-10       Impact factor: 2.649

8.  Quantitation of apoptotic activity following castration in human prostatic tissue in vivo.

Authors:  Andrea Staack; Adrienne P Kassis; Adam Olshen; Yuzhuo Wang; David Wu; Peter R Carroll; Gary D Grossfeld; Gerald R Cunha; Simon W Hayward
Journal:  Prostate       Date:  2003-02-15       Impact factor: 4.104

9.  Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.

Authors:  Michael Stanbrough; Glenn J Bubley; Kenneth Ross; Todd R Golub; Mark A Rubin; Trevor M Penning; Phillip G Febbo; Steven P Balk
Journal:  Cancer Res       Date:  2006-03-01       Impact factor: 12.701

10.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

View more
  6 in total

Review 1.  Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses.

Authors:  Laura N Vandenberg; Theo Colborn; Tyrone B Hayes; Jerrold J Heindel; David R Jacobs; Duk-Hee Lee; Toshi Shioda; Ana M Soto; Frederick S vom Saal; Wade V Welshons; R Thomas Zoeller; John Peterson Myers
Journal:  Endocr Rev       Date:  2012-03-14       Impact factor: 19.871

2.  Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells.

Authors:  Harris S Soifer; Naira Souleimanian; Sijian Wu; Anatoliy M Voskresenskiy; Filiz Kisaayak Collak; Bekir Cinar; Cy A Stein
Journal:  J Biol Chem       Date:  2011-12-15       Impact factor: 5.157

3.  Effects of manganese superoxide dismutase silencing on androgen receptor function and gene regulation: implications for castration-resistant prostate cancer.

Authors:  Nima Sharifi; Elaine M Hurt; Suneetha B Thomas; William L Farrar
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

4.  A feedback loop between the androgen receptor and a NEDD4-binding protein, PMEPA1, in prostate cancer cells.

Authors:  Hongyun Li; Linda L Xu; Katsuaki Masuda; Eliza Raymundo; David G McLeod; Albert Dobi; Shiv Srivastava
Journal:  J Biol Chem       Date:  2008-08-14       Impact factor: 5.157

5.  A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer.

Authors:  Nima Sharifi; Akinobu Hamada; Tristan Sissung; Romano Danesi; David Venzon; Caitlin Baum; James L Gulley; Douglas K Price; William L Dahut; William D Figg
Journal:  BJU Int       Date:  2008-06-04       Impact factor: 5.588

6.  Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer.

Authors:  Akinobu Hamada; Tristan Sissung; Douglas K Price; Romano Danesi; Cindy H Chau; Nima Sharifi; David Venzon; Kenji Maeda; Keisuke Nagao; Alex Sparreboom; Hiroaki Mitsuya; William L Dahut; William D Figg
Journal:  Clin Cancer Res       Date:  2008-06-01       Impact factor: 12.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.